Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.05), Zacks reports.
Akebia Therapeutics Price Performance
Shares of NASDAQ AKBA opened at $1.80 on Thursday. The firm has a market capitalization of $391.85 million, a PE ratio of -7.80 and a beta of 0.94. Akebia Therapeutics has a 1-year low of $0.80 and a 1-year high of $2.48. The business's fifty day moving average price is $2.02 and its two-hundred day moving average price is $1.78.
Wall Street Analyst Weigh In
Several research firms have weighed in on AKBA. HC Wainwright reiterated a "buy" rating and set a $7.50 target price on shares of Akebia Therapeutics in a research note on Thursday, January 23rd. StockNews.com downgraded shares of Akebia Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, March 6th.
Read Our Latest Report on AKBA
Insider Activity
In other news, SVP Steven Keith Burke sold 50,506 shares of Akebia Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $106,062.60. Following the sale, the senior vice president now owns 816,234 shares of the company's stock, valued at approximately $1,714,091.40. The trade was a 5.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO John P. Butler sold 144,250 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total value of $302,925.00. Following the completion of the transaction, the chief executive officer now directly owns 2,604,330 shares of the company's stock, valued at $5,469,093. This trade represents a 5.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 280,579 shares of company stock valued at $589,216. 4.10% of the stock is currently owned by company insiders.
About Akebia Therapeutics
(
Get Free Report)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Akebia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.
While Akebia Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
